Vaprisol (conivaptan injection) / Cumberland - LARVOL DELTA

Vaptans for edematous and hyponatremic disorders in childhood: a systematic literature review. (PubMed, Br J Clin Pharmacol) - "Vaptans appear to be safe for edematous and hyponatremic disorders also in children. Although they increase diuresis and natremia, no superiority to traditional diuretics and sodium supplements has been demonstrated. Reported side effects are rare and non-serious."

Journal • Review • Cardiovascular • Dental Disorders • Dermatology • Xerostomia

ADDING UREA THERAPY FROM THE 1890'S TO 21ST CENTURY STANDARD OF CARE (ISN-WCN 2022) - "Vasopressin antagonists like tolvaptan (PO) and conivaptan (IV) are another option in these difficult to treat patients, but use is limited due to availability, price, and side effects that include liver failure, overcorrection, and increased thirst...His medications included bumetadine, empagliflozin, levothyroxine, diltiazem, digoxin, rifampin, linezolid, and ethambutol...The patient was started on loop diuretic therapy for volume overload with bumetanide 2mg every 12 hours, later optimized to 3mg every 12 hrs... Diuretic resistance and hyponatremia are a common limitation for standard of are therapy in patients with volume overload. Urea, as an osmotic diuretic, increases free water loss, therein improving sodium levels whilst promoting diuresis. The addition of urea to loop diuretics would be a less expensive way to treat these patients with hypervolemic hyponatremia not responding to loop diuretics alone."

Cardiovascular • Congestive Heart Failure • Endocrine Disorders • Gastrointestinal Disorder • Heart Failure • Hematological Malignancies • Hepatology • Hodgkin Lymphoma • Infectious Disease • Liver Failure • Lymphoma • Oncology • Pain • Respiratory Diseases

Efficacy of vaptans for correction of postoperative hyponatremia: A comparison between single intravenous bolus conivaptan vs oral tolvaptan. (PubMed, J Anaesthesiol Clin Pharmacol) - "Single-dose intravenous conivaptan as well as oral tolvaptan were safe and effective in correcting hyponatremia in postoperative patients. Conivaptan could be considered superior as it resulted in faster sodium correction with effective aquaresis."

Clinical • Journal • Biosimilar • Cardiovascular • Heart Failure

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study (clinicaltrials.gov) - P1; N=7; Completed; Sponsor: Jesse Corry; Phase classification: P=N/A ➔ P1

Clinical • Phase classification • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders

Vasopressin antagonism for decompensated right-sided heart failure. (PubMed, Int J Cardiol) - "Vaptans were associated with a significant increase in urine output and serum sodium with an apparent reduction or stabilization of furosemide equivalent dosing in the early treatment period in patients with decompensated RHF. Vaptans may offer a management option for patients failing conventional diuretic-based treatment."

Journal

Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients with chronic heart failure during submaximal exercise. (PubMed, Am Heart J) - No abstract available.

Clinical • Journal

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study (clinicaltrials.gov) - P=N/A; N=7; Completed; Sponsor: Jesse Corry; Enrolling by invitation ➔ Completed; Trial completion date: Jan 2020 ➔ Apr 2019; Trial primary completion date: Jan 2020 ➔ Feb 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date

Effects of Conivaptan versus Mannitol on Post-Ischemic Brain Injury and Edema. (PubMed, Eurasian J Med) - "Our findings revealed that conivaptan shows more diuretic activity than mannitol and triggers neither any damages nor edema in the brain tissue. This study may provide beneficial information for the development of treatment strategies for ischemia-related cerebrovascular diseases."

Journal

"I gather conivaptan is pretty useless in hepatic hyponatraemia. Perhaps this is one of the reasons why." (@jfdwolff)

"Question, if terlipressin is good for hepatorenal syndrome (HRS) by binding V1 and V2 receptors, shouldn't conivaptan induce or worsen HRS by blocking V1 and V2 receptors? @VelezNephHepato" (@kidney_boy)